Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
Healthcare
$9.13 +0.66%
+$0.13 today
- Market cap
- $821.96M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
52W Low $8.59High $25.59
Volume 3.30M
Average 1.70M
Income Statement
Follow revenue through to earnings.
Revenue
$172.35M
FY 2025 · Annual
+627.8% YoYOperating Income
-$273.08M
FY 2025 · Annual
Net Income
-$285.42M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.71M | 0 | 0 | 23.68M | 172.35M |
| Cost of Revenue | 0 | 0 | 0 | 826K | 6.97M |
| Gross Profit | 139.71M | 0 | 0 | 22.85M | 165.38M |
| Gross Margin | 100.0% | — | — | 96.5% | 96.0% |
| Research & Development | 88.25M | 118.5M | 163.03M | 241.65M | 258.78M |
| Selling, General & Admin | 25.24M | 33.26M | 66.92M | 120.88M | 179.68M |
| Operating Expenses | 113.49M | 151.76M | 229.95M | 362.53M | 438.47M |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| EBITDA | 26.87M | (146.17M) | (209.14M) | (313.82M) | (251.63M) |
| EBITDA Margin | 19.2% | — | — | -1325.3% | -146.0% |
| Operating Income | 26.22M | (151.76M) | (229.95M) | (339.67M) | (273.08M) |
| Operating Margin | 18.8% | — | — | -1434.4% | -158.4% |
| Interest Income | 403K | 5.87M | 21.16M | 26.09M | 22.73M |
| Interest Expense | 1.9M | 3.14M | 208K | 4.93M | 33.79M |
| Other Income / Expenses | (1.29M) | 2.42M | 20.59M | 20.91M | (12.34M) |
| Income Before Tax | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Pre-Tax Margin | 17.8% | — | — | -1346.1% | -165.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Net Margin | 17.8% | — | — | -1346.1% | -165.6% |
| EPS (Basic) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| EPS (Diluted) | 0.48 | (2.46) | (2.98) | (3.73) | (3.29) |
| 52.06M | 60.76M | 70.37M | 85.62M | 86.63M | |
| 52.06M | 60.76M | 70.37M | 85.62M | 86.63M |
SNDX Earnings Waterfall · TTM
NASDAQ:SNDX · Revenue to Net Income
Key Ratios
EPS$-2.80
Gross Margin97.6%
Net Margin-121.7%
P/E Ratio-6.7
P/S Ratio27.0
Analysis
$217.2M of revenue converted into -$243.2M of net income for the selected period. Gross margin is 97.6% and net margin is -121.7%, showing how much revenue survives after costs and taxes. EPS is $-2.80, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 2, 2026 | |
| 8-K | Current report | Nov 2, 2026 |
How much revenue does SNDX generate?
Syndax Pharmaceuticals, Inc. (SNDX) reported $172.35M of revenue in fiscal 2025.
Is SNDX profitable?
Syndax Pharmaceuticals, Inc. (SNDX) reported -$285.42M of net income, with a net margin of -165.6%.
Continue the stock analysis
Jump to another research area for this company.